BioCardia Elects Marvin Slosman to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: Newsfilter
- New Board Appointment: BioCardia announced the election of Marvin Slosman to its Board of Directors effective December 2, 2025, bringing deep expertise in interventional cardiology that is expected to drive innovation and market expansion in cardiovascular disease treatment.
- Rich Leadership Experience: Slosman, who previously served as CEO of InspireMD and held senior commercial leadership roles at Johnson & Johnson, GE Healthcare, and Baxter International, brings extensive market development and product commercialization experience that will aid BioCardia's strategic growth.
- Gratitude to Former Director: BioCardia expressed appreciation for departing board member Richard Krasno, who provided guidance during key milestones, particularly in the FDA approval of the CardiAMP cell therapy and the Morph DNA product.
- Strategic Company Development: The appointment of Slosman is expected to significantly support BioCardia's clinical value creation and global market expansion, further advancing the company's innovative solutions for treating cardiovascular and pulmonary diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCDA
Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is 15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.300
Low
6.00
Averages
15.50
High
25.00
Current: 1.300
Low
6.00
Averages
15.50
High
25.00
No data
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
Continue Reading
BioCardia Completes Third Clinical Consultation with Japan's PMDA for CardiAMP Therapy
- Clinical Consultation Progress: BioCardia has completed its third preliminary clinical consultation with Japan's PMDA, preparing for formal discussions on the CardiAMP therapy for heart failure, which could pave the way for new treatment options in the Japanese market.
- Efficacy Data Support: Data from three clinical trials indicate that CardiAMP therapy shows positive outcomes in improving survival rates and reducing major adverse cardiovascular events, highlighting its potential value in treating heart failure patients.
- Innovative Treatment Mechanism: The CardiAMP cell therapy utilizes the patient's own bone marrow cells delivered via a minimally invasive catheter procedure to repair microvascular dysfunction, offering a new therapeutic option for ischemic heart failure patients.
- Clear Regulatory Pathway: The PMDA has indicated that BioCardia can advance to formal clinical consultation, and if the data sufficiently supports safety and efficacy, it will facilitate the company's application for regulatory approval in Japan, further driving its expansion in the Asia-Pacific market.
Continue Reading